SynAm Vaccine, located in Rockville, Maryland, is a pioneering biotech company dedicated to eradicating pneumococcal diseases such as pneumonia, middle ear infections, and meningitis through the development of the world's first universal vaccine. Their lead vaccine candidate provides universal coverage against all 91 bacteria serotypes, addressing a critical unmet medical need in the market.
With a mission to combat serious illnesses in both children and adults, SynAm Vaccine aims to surpass the limited coverage of current vaccines by offering a comprehensive solution that goes beyond the fraction of serotypes covered by existing options. Their team of experienced professionals, including renowned scientific advisors, is committed to making a significant impact in the field of vaccine development.
Generated from the website